ProMetic’s potential blockbuster lead small molecule candidate continues to deliver positive data from the clinic, with a series of trials starting to translate the compelling pre-clinical studies into efficacy in humans. This week’s announcement confirmed a significant reduction in established liver fibrosis in 100% of the first five patients who completed 12 weeks of treatment in the open label trial. CMO John Moran stated in the subsequent conference call, that ultra-orphan Als
13 Oct 2016
Alström syndrome phase II read outs show significant reduction in liver fibrosis
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Alström syndrome phase II read outs show significant reduction in liver fibrosis
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
13 Oct 2016 -
Author:
Derren Nathan -
Pages:
6
ProMetic’s potential blockbuster lead small molecule candidate continues to deliver positive data from the clinic, with a series of trials starting to translate the compelling pre-clinical studies into efficacy in humans. This week’s announcement confirmed a significant reduction in established liver fibrosis in 100% of the first five patients who completed 12 weeks of treatment in the open label trial. CMO John Moran stated in the subsequent conference call, that ultra-orphan Als